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ABSTRACT
Early results from the National Health Service Sickle Cell
and Thalassaemia Screening programme covering the
whole of England are reported following the implemen-
tation of the national newborn blood-spot screening
programme. Of the 13 laboratories performing screening,
10 chose high-performance liquid chromatography as the
first screen, with isoelectric focusing as the second
confirmatory test. Screening results for April 2005 to
March 2007 are presented and include data from all the
laboratories screening newborns in England, and almost
1.2 million infants. The screen-positive results show a
national birth prevalence of almost 1 in 2000. The birth
prevalence in London is five times that of most of the rest
of the country. Over 17000 carriers have been identified.
Approximately seven per 1000 samples are reported as
post-transfusion with wide ethnic category variation.
Given the prevalence of the conditions, and coverage by
ethnicity, 3–4 screen-positive cases could be missed each
year. National implementation of newborn screening in
England has increased the number of children identified
with sickle cell disease, in many areas almost doubling
the workload. Underascertainment of the condition has
allowed a downplaying of the scale of need. It may also
have contributed to infant mortality rates in urban areas
as babies died without a diagnosis or treatment. The
value of a co-ordinated national approach to policy
development and implementation is emphasised by the
English experience. The programme provides a model for
Europe as well as other countries with significant minority
populations, such as Canada. Potentially it also offers
important lessons for Africa where the World Health
Organization is supporting the introduction of newborn
screening.
In England the National Health Service (NHS) Plan
published in 2000 gave a commitment to implement
a linked antenatal and newborn haemoglobinopathy
and sickle cell disease (SCD) screening programme
by 2004.
1 This was the culmination of many years of
lobbying and reports making the case for screening
of newborns.
2–4 It followed consideration by, and
support of, the Children’s Sub-group of the UK
National Screening Committee (NSC) from the
evidence of two Health Technology Assessments
on the subject of newborn and antenatal screening
for haemoglobinopathies.
56 These Health
Technology Assessments supported the introduc-
tion of newborn screening for SCD using a mixture
of universal and targeted approaches according to
the prevalence of the condition.
56
Working within this policy framework, and
incorporating advice from an international work-
shop held in 2001, the NHS Sickle Cell and
Thalassaemia Screening Programme recommended
to the Children’s Sub-group of the NSC that
newborn screening offered to all babies, be
recommended as the only practical and equitable
solution to adopt.
7 This recommendation was
accepted in February 2002.
Only those haemoglobin (Hb) gene combina-
tions that are clinically significant were specified
for inclusion in the national screening programme.
They are: HbSS, HbSC, HbSD-Punjab, HbS btha-
lassaemia, HbSO-Arab and HbSHPFH (hereditary
persistence of fetal Hb).
The programme also recommended that other
clinically significant conditions should be referred
for clinical follow-up. These were conditions that
did not meet the criteria for screening but were
clinically significant and were likely to be detected
by the methods used.
89These are: b thalassaemia
major, b thalassaemia intermedia, HbH disease,
HbE/b thalassaemia and HbSE.
10 The UK NSC
recommended that the programme should not aim
to identify combinations that are not clinically
significant since there is no evidence that their
detection leads to any benefit, and detection may,
in fact, lead to harm through unnecessary medica-
lisation.
9 The NSC supported the recommendation
by the programme that, in line with pre-existing
practice in areas already undertaking newborn
screening, carriers of the main haemoglobins
including S, C, D and E should be reported to
parents. This was a controversial area, with many
clinical geneticists considering that this informa-
tion should be withheld.
11 The UK decision is in
line with the recent review undertaken in the
USA.
12
METHODS
To prepare for national roll-out it was necessary to
assess the readiness of the health service for
implementation. An initial survey of health autho-
rities and trusts undertaken in 2001 to assess
readiness for implementation and support for
implementation showed that there were signifi-
cant challenges in terms of attitudes and lack of
support from policy makers, health authorities and
service providers for the programme.
13 There was
stronger support for the programme in higher
prevalence areas although this was not comple-
tely consistent. The survey also suggested that
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a basis on which to build.
13
To support the implementation of the programme, regional
mapping exercises were undertaken for all regions of the
country to attempt to identify care pathways for the care of
affected children where these existed, or to highlight the need
for these to be developed where they did not exist. These
reports are all available on the programme website including
flow-charts showing the care pathways that existed at the start
of the programme.
14 In some areas there was no such care
pathway and no arrangements for communication of carrier
results.
In addition, a survey of existing practice among the four
laboratories already screening using dried blood spots showed
that the majority employed high-performance liquid chromato-
graphy (HPLC) followed by isoelectric focusing (IEF) for
confirmation, with one laboratory using IEF with no immediate
confirmatory test. There was wide variation in the cost per test
charged by commercial companies to these laboratories and to
standardise quality and prices, national procurement was
undertaken. This obviated the necessity for individual labora-
tories to go out to tender for equipment and ensured that
equipment selected was the most suitable for the screening
protocol chosen. In particular, automated HPLC equipment
from the USA needed to be adapted for the UK market to take
account of the different age at which testing is currently
performed in the UK (5–8 days compared with earlier in the
USA and elsewhere). The equipment had previously not been
available in Europe.
To support the development of policy, various subgroups
were established, including a laboratory subgroup and a training
and education subgroup. The laboratory subgroup drew
representation from the various relevant professionally led
organisations and societies, as well as the recognised experts
in the field, both clinicians and scientists. From this a plan for
implementation was developed for each region or catchment
area covered by a laboratory. The programme required the
development and implementation of training for front-line staff
involved with the programme, particularly midwives, and for
this training to have been undertaken before implementation
could proceed. The programme also liaised with a major quality
assurance (QA) scheme and worked closely to support the
development of a bespoke quality assurance for newborn
screening based on dried blood spots to run alongside the
existing liquid sample scheme.
15 Most areas of policy are now
clarified but work is ongoing to develop a consensus regarding
unidentified variants and Hb Bart’s reporting, emphasising the
need for better data on costs and benefits and further research.
The methods recommended by the programme were for an
initial screening test using either HPLC or IEF to be performed
with the biochemical screening already taking place for
phenylketonuria and hypothyroidism. For initial screen-positive
tests, a confirmatory test using a different technique was
recommended. The decision to use two-stage testing to
minimise incorrect identification of abnormal haemoglobins
and ensure a high level of quality was based on the experience of
the UK laboratories already using this approach and the USA,
which had not routinely used a second test.
7 The increase in
workload implied by the roll-out for the West Midlands
laboratory who were screening 15 000, and would increase to
approximately 70 000 per annum, prompted an evaluation of
available methodologies and the potential of each for automa-
tion. A primary focus was the potential of the technology
to permit positive specimen identification (blood-spot card
accession number) to follow a baby’s blood spot electronically
from the punched disk to the analytical result.
In addition to providing start-up funding for laboratory
development, funding for the development of adequate counsel-
ling services for affected infants and carriers identified by the
programme was provided. All trusts were required to nominate
a paediatrician to be the named local contact; this was especially
important and difficult in lower prevalence areas where most
care would be undertaken by a specialist unit distant from the
local area. Materials to support communication with parents
included a general ‘‘antenatal and newborn leaflet covering all
screening including bloodspot screening’’ giving information on
sickle cell disease
16 and two carrier leaflets – one for HbS
carriers
17 and one for carriers of other haemoglobins.
18
Implementation in the laboratories was supported by the
production of a handbook
10 detailing reporting formats and
referral pathways. Ten standards of laboratory practice were
produced covering accreditation, turnaround times and QA
performance, and annual data returns were required to help
monitor coverage and pick-up rates. We are currently working
on status codes to relay information to the child health network
and assist linkage with the antenatal programme. The
programme has set national standards and is developing a QA
programme covering all aspects of the screening and care
pathway.
19 20
Planning of service capacity was based on epidemiological
estimates provided by Professor Bernadette Modell.
21 This gave
estimates by area of the number of affected infants and carriers
likely to be identified to ensure that resources and staffing were
appropriate for the numbers expected.
These initial estimates were lower than the numbers from the
early stages of implementation of screening. Subsequent
estimates have been incorporated into the materials for the
programme-funded national training programme called the
‘‘PEGASUS programme’’ for which Modell provided the public
health module that incorporates estimates of need for newborn
and antenatal screening. The other two modules of this
programme were cascade training of trainers and materials to
support ‘‘front line professionals’’ and specialist training for
counsellors.
22 Implementation was planned in four phases. A
phased approach was adopted for several reasons. First, some
high-prevalence areas, mainly in London, were already offering
screening, and the programme wanted to build on the
Table 1 Rates of significant conditions* per 1000 screened babies:
April 2005 to March 2007
Results for newborns:
April 2005 to March
2007
Significant conditions*
No. of babies
screened
Rate per 1000
babies screened No.
North East 0.12 6 49 321
North West 0.24 40 169 498
Yorkshire and The
Humber
0.24 29 119 616
East Midlands 0.25 24 96 876
West Midlands 0.28 38 133 905
East of England 0.32 39 123 794
London 1.82 436 239 654
South East coast 0.14 14 97 954
South central 0.21 10 47 835
South West 0.12 11 90 520
Unknown ,5 29 641
England 0.54 651 1 198 614
*Significant conditions comprise the following results: FS, FSC, FS other conditions,
and FE.
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implement screening universally based on the blood-spot
programme already in place for newborn phenylketonuria and
hypothyroidism screening. Prior to the implementation of sickle
screening there were 20 biochemical laboratories with work-
loads ranging from 6000 to 100 000 specimens per annum.
Information from a Health Technology Assessment report
suggested that laboratories should cover at least 25 000 samples
a year to be cost effective.
5 This meant a reduction in the
number of laboratories to 13, and this required commissioning
engagement and reorganisation of services, and inevitably
delayed implementation in some areas. In some areas ‘‘targeted
screening’’ using cord blood methods needed to be discontinued
to avoid duplication of effort and this was not always readily
accepted.
The extent to which the managers in the NHS engaged with
this process was significantly affected by a lack of coherence of
government policy partly due to a major reorganisation of the
NHS at this time and a lack of clarity as to where the
responsibility for commissioning screening services lay—with
arguments in many areas between local and regional commis-
sioners and lack of ownership making securing the pick-up of
funding following the start of the programme a significant
challenge. These issues are now resolved but did delay
implementation to some degree. Implementation in England
started in September 2003 and was completed in July 2006.
Implementation is planned for Scotland by 2010 but no date has
yet been set for implementation in Wales and Northern Ireland.
RESULTS
Of the 13 laboratories now undertaking newborn sickle cell
screening 10 chose HPLC as the first screen, with IEF as the
second confirmatory test. This second test is generally referred
to laboratories with haematological expertise—either on-site or
elsewhere.
Findings of the early stages of implementation prior to the
complete introduction of the programme have previously been
published.
23 Screening results for the 2 years from April 2005 to
March 2007 are shown in table 1. This provides almost complete
information for the whole country (with the exception that
Portsmouth provided data from April 2006, and Oxford from
July 2006.). It includes reports from all the laboratories
screening newborns in England, covering almost 1.2 million
infants. Significant conditions comprise the following results:
FS, FSC, FS other and FE (see supplementary table for detailed
information on screening results and diagnostic possibilities). The
supplementary table shows that the birth prevalence of screen-
positive results—as listed in the boxes for the major conditions—
shows a national birth prevalence of just above one in 2000. More
than 300 screen-positive results are detected by newborn screen-
ing each year. The table also shows that birth prevalence in
London is five times that of most of the rest of the country.
Over 17 000 carriers have been identified in the 2 years.
Table 2 shows that over half of all carriers are identified in
London but significant numbers of carriers are also being
reported from the North West (includes Manchester), West
Midlands (includes Birmingham), East of England Region
(includes Essex) and East Midlands (includes Leicester and
Nottingham). Table 3 shows that approximately seven per 1000
samples are reported as post-transfusion with wide ethnic
category variation. Given the prevalence of the conditions, and
coverage by ethnicity this is likely to represent 3–4 screen-
positive cases missed each year.
24 As a result of implementing
haemoglobinopathy screening in the newborn period two cases
where adult not newborn blood was on the card have also been
identified; this is relevant for all the conditions screened for. An
associated difficulty for the programme is the follow-up of
premature infants.
Birmingham was unable to provide transfused data due to
variations in coding of ethnic category and laboratory software
constraints and Bristol was unable to provide transfused data
for the first half of 2005. Total numbers were reduced
accordingly.
The West Midlands evaluation reviewed four systems: Akron
IEF from Perkin Elmer, Primus Corporation HPLC, Bio-Rad
Variant and Bio-Rad NHS (later known as NBS) HPLC systems.
The main findings was that the Bio-Rad NBS HPLC system,
which had been developed for the California State Newborn
Screening Service, permitted full positive specimen identifica-
tion, the crispest chromatograms and large workloads using a
Table 2 Carrier* rates per 1000 babies screened: April 2005 to March
2007
Results for newborns:
April 2005 to March
2007
Carrier
No. of babies
screened
Rate per 1000
babies screened No.
North East 4.26 210 49 321
North West 7.89 1338 169 498
Yorkshire and The Humber 8.27 989 119 616
East Midlands 8.37 811 96 876
West Midlands 12.63 1691 133 905
East of England 10.18 1260 123 794
London 39.92 9566 239 654
South East coast 6.01 589 97 954
South central 8.30 397 47 835
South West 4.49 406 90 520
Unknown 3.91 116 29 641
England 14.49 17373 1 198 614
*Carrier status comprise the following results: FAS, FAC, FAD, FAE and other carrier.
Table 3 Transfused rates per 1000 babies screened: April 2005 to
March 2007
Results for newborns:
April 2005 to March
2007
Transfusions
No. of babies
screened
Rate per 1000
screened babies No.
White British 5.35 3554 664 710
White Irish 10.24 20 1953
Any other white
background
5.33 214 40 126
White and black Caribbean 8.88 91 10 246
White and black African 5.83 32 5493
White and Asian 5.89 54 9164
Any other mixed
background
7.23 115 15 912
Indian 6.67 165 24 744
Pakistani 6.55 211 32 214
Bangladeshi 6.83 100 14 649
Any other Asian
background
7.24 85 11 738
Black Caribbean 16.62 208 12 512
Black African 12.87 524 40 728
Any other black
background
16.56 55 3322
Chinese 11.20 54 4821
Any other ethnic category 8.58 215 25 051
Not stated 12.74 1679 131 828
England 7.03 7376 1 049 211
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haemoglobin discrimination, was a close second in respect of
automation. The algorithms in the HPLC software also needed
amending to fit England’s later age of screening specimen;
specifically around the amount of HbA present. This work
informed the implementation.
More detailed information by local area, type of condition
and carrier status will be available in due course. This will allow
an update of the modelling data used to estimate expected
numbers of carriers and disease states.
DISCUSSION
National implementation of newborn screening in England has
increased the number of children identified with SCD, in many
areas almost doubling the workload over a few years. This
shows how underascertainment of the condition has in the past
allowed a downplaying of the needs of people with these
conditions. It may also have contributed to infant mortality
rates in urban areas as babies died without the diagnosis having
been made and treatment instituted.
25 26 Since the introduction
of the programme older siblings who were previously undiag-
nosed have also been referred to specialist centres.
The value of a co-ordinated national approach to policy
development and implementation is emphasised by the English
experience. The programme developing provides a model for
Europe to consider as well as other countries with significant
ethnic minority populations, such as Canada. Potentially it also
offers important lessons for implementation of programmes in
Africa where the burden of disease is significant and where the
World Health Organization is supporting the introduction of
screening of newborns.
27–29
In planning implementation it is important to use estimates
that can be adapted as information becomes available to ensure
that service capacity is put in place as appropriate. Our
experience is that this may still lead to an underestimate of
need – see current information available.
30 The national
approach allowed the development of national materials and
training programmes that make much more efficient use of
limited resources and should ensure consistency of information
and messages; this was not always the case previously. The
technology and screening methods are excellent compared with
the standards that some screening programmes have had to live
with (such as cancer screening programmes where much lower
specificity and sensitivity is achieved). The programme has also
driven, and continues to drive, further developments in
methods.
31 32 Adaptation of equipment for the UK and ongoing
developments suggest that the UK provides a good site for
development of screening techniques and methods.
Evidence suggests that when carried out correctly, the
sensitivity and specificity of HPLC and IEF is close to 100%,
and therefore these are very reliable methods to use for a
screening programme. This does not, of course, mean that there
will never be a missed case. Attention to technical detail
remains essential if such high standards are to be maintained
after the excitement of the early days of the programme. It is
important to take account of the usual age of sampling in
different countries to ensure, for example, that the algorithms
in the HPLC software take account of the percentage of HbA
expected at different ages.
Remaining challenges, such as the best approach for a
screening programme for unidentified variants and Hb Bart’s,
emphasise the need for better data and research that England,
with its consistent approach and increasing population, and
assuming adequate resourcing, is well placed to do. This work is
likely to be useful to other countries.
Those working in a laboratory may consider the technical
aspects the most important but for the development of a
successful programme all key stakeholders need to be engaged
and development of training, counselling and clinical follow-up
is crucial to the establishment of a successful programme. It
goes without staying that user and voluntary sector support are
important and a key reason for the success of the programme
has been the multidisciplinary steering group led by a strong lay
chairperson (now Archbishop of York, who is himself originally
a refugee from the time of Idi Amin) to ensure that at all times
the screening programme takes account of the user perspective.
Implementing a programme that involves identifying a large
number of genetic carriers of a recessive condition must not be
undertaken as a technical exercise. Wide community engage-
ment and support are essential. There is still a considerable way
to go with improving understanding in the communities at
highest risk.
SUMMARY STATEMENT
The commitment of the UK government to introducing a linked
newborn and antenatal screening programme is nearly achieved
for England. A good programme is being developed that provides
a model for the rest of the UK and for other countries in Europe,
although challenges remain to be addressed and services for the
care of affected patients require considerable development to
keep up with the scale of the conditions revealed by the
programme. The experience of implementing this programme
could, with modification, provide a model and expertise to
support developments of newborn screening programmes in
Africa.
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